News | October 27, 2014

Miracor Begins European Launch of New PICSO Impulse System

System designed to reduce severe heart attack impairment as an adjunct therapy with angioplasty in acute STEMI and NSTEMI patients

October 27, 2014 — Miracor Medical Systems announced today the successful launch of its next-generation Pressure-Controlled Intermittent Coronary Sinus Occlusion (PICSO) Impulse System for the treatment of myocardial infarction. The new PICSO Impulse System, consisting of the Impulse Console and Impulse Balloon Catheters, is CE-marked and has already been used to treat patients in the U.K., Ireland and Hungary.

PICSO is designed to increase myocardial perfusion in conjunction with primary percutaneous coronary intervention (PCI) or angioplasty and thereby reduce infarct size and improve cardiac function. To date nearly 160 patients have been treated, and the most recent clinical trial data presented at EuroPCR 2014 confirmed the significant impact of the Miracor PICSO technology on infarct size-reduction in patients who had received PICSO therapy following PCI compared to a control group. Additionally the data confirmed the safety profile of the PICSO technology.

A new, smaller balloon catheter now addresses variable patient anatomies as well as physician preferences and provides improved handling and increased balloon stability during PICSO therapy.

“I was able to place the balloon very easily in the coronary sinus and immediately achieved a stable position,“ said Prof. Béla Merkely, M.D., chairman and director at the Semmelweis University Heart and Vascular Center in Budapest, Hungary, after using the new PICSO therapy in a ST-segment elevation myocardial infarction (STEMI) and a non-STEMI patient.

“The system provided continuous and stable therapy during my coronary intervention, and I look forward now to see the long-term benefits for our patients with myocardial infarction,” added Levente Molnár, M.D., from the Semmelweis University Heart and Vascular Center.

The PICSO Impulse System’s console and software also have been updated to facilitate faster, safe and effective therapy delivery. Piers Clifford, M.D., cardiology consultant and clinical lead for cardiology, Buckinghamshire Healthcare NHS, who used the new PICSO Impulse System at the Wycombe Hospital in High Wycombe, Buckinghamshire, U.K., commented: “I’m very pleased to see the advancements that have been made to the PICSO system, which now make it even easier and faster to use without interrupting our workflows. I’m convinced that the PICSO Impulse System will change the way we treat patients with ST-segment elevation and non-ST-segment elevation myocardial infarction.”

For more information: www.miracormedical.com

Related Content

Treatment of Heart Attack Patients Depends on Cancer History
News | Cardio-oncology| September 26, 2017
Treatment of heart attack patients depends on their history of cancer, according to research published recently in...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Overlay Init